Table 2.

Serum concentrations of CRP by tumor characteristics in breast cancer survivors of the WHEL study

Distribution of inflammatory status
No inflammationLow inflammationModerate inflammationAcute inflammation
Serum CRP mg/L<1 mg/L1–3 mg/L>3 to <10 mg/L≥10 mg/L
n (%)Geometric meanNo.%No.%No.%No.%P
Tumor stage0.007
 I1,144 (39.2)1.54 (0.58, 3.91)41842.636038.627736.98934.9
 II1,333 (45.7)1.73 (0.71, 4.17)52753.753857.742456.515058.8
 IIIA442 (15.1)2.2 (0.94, 5.55)363.7353.8496.5166.3
Tumor grade0.097
 1, Well differentiated463 (15.9)1.51 (0.54, 4.23)18118.513114.010914.54216.5
 2, Moderately differentiated1,184 (40.6)1.64 (0.66, 3.88)39740.539542.330240.39035.3
 3, Poorly differentiated1,027 (35.2)1.92 (0.77, 4.87)31632.233135.527837.110240.0
 Unspecified245 (8.4)1.66 (0.63, 4.04)878.9768.1618.1218.2
Estrogen/PR status0.003
 ER+/PR+1,818 (62.3)1.60 (0.64, 4.02)63164.359764.045961.213552.9
 ER+/PR331 (11.3)1.53 (0.63, 3.83)12112.310611.48411.2228.6
 ER/PR+121 (4.2)1.73 (0.57, 4.35)424.3333.5344.5124.7
 ER/PR582 (19.9)2.20 (0.85, 5.50)17017.317919.215420.57830.6
 Unknown67 (2.3)2.20 (0.91, 6.06)171.7181.9192.583.1
HER2 receptor status0.605
 Positive360 (12.3)1.72 (0.66, 4.22)12312.510811.610013.32911.4
 Negative1,672 (57.3)1.74 (0.70,4.26)54255.254358.243858.414958.4
 Unknown887 (30.4)1.66 (0.65, 4.17)31632.228230.221228.37730.2
Treatment (after surgery)0.597
 No chemotherapy or radiation321 (11.0)1.56 (0.58, 3.86)11211.410611.4749.92911.4
 Radiation only569 (19.5)1.63 (0.66, 4.00)19620.019320.714018.74015.7
 Chemotherapy only794 (27.2)1.76 (0.66, 4.17)25526.025827.720527.37629.8
 Radiation and chemotherapy1,230 (42.1)1.76 (0.71, 4.56)41542.337540.233144.110942.7
 Unknown5 (0.17)0.85 (0.25, 2.68)30.310.100.010.4
Current anti-estrogen use<0.001
 Yes1,796 (61.5)1.54 (0.63, 3.92)64065.258662.844959.912147.5
 No1,119 (38.3)2.03 (0.80, 5.10)34134.834336.830140.113452.5
 Unknown4 (0.13)1.75 (1.29, 2.37)00.040.400.000.0

NOTE: P values were calculated using χ2 tests for categorical variables.